Israel Englander Ardelyx, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Ardelyx, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 11,663,229 shares of ARDX stock, worth $65.3 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,663,229

Previous 6,465,262 80.4%

Holding current value

$65.3 Million

Previous $31.7 Million 44.02%

% of portfolio

0.02%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$3.28 - $5.51 $17 Million - $28.6 Million	5,197,967 Added 80.4%	11,663,229 $45.7 Million
Q1 2025 May 15, 2025	BUY	$4.91 - $6.36 $17.2 Million - $22.3 Million	3,501,782 Added 118.16%	6,465,262 $31.7 Million
Q4 2024 Feb 14, 2025	SELL	$4.49 - $6.85 $4.71 Million - $7.18 Million	-1,048,400 Reduced 26.13%	2,963,480 $15.3 Million
Q3 2024 Nov 14, 2024	BUY	$5.28 - $7.57 $4.27 Million - $6.12 Million	808,790 Added 25.25%	4,011,880 $27.6 Million
Q2 2024 Aug 14, 2024	BUY	$5.89 - $9.31 $11.1 Million - $17.5 Million	1,883,995 Added 142.82%	3,203,090 $23.7 Million
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $7.98 Million - $12.8 Million	1,319,095 New	1,319,095 $9.63 Million
Q2 2023 Aug 14, 2023	SELL	$3.23 - $4.95 $13.1 Million - $20 Million	-4,043,377 Reduced 36.69%	6,976,230 $23.6 Million
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $1.71 Million - $3.05 Million	636,278 Added 6.13%	11,019,607 $52.8 Million
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $11.5 Million - $26.9 Million	9,435,291 Added 995.24%	10,383,329 $29.6 Million
Q3 2022 Nov 14, 2022	SELL	$0.59 - $1.44 $353,330 - $862,367	-598,866 Reduced 38.71%	948,038 $1.13 Million
Q2 2022 Aug 15, 2022	BUY	$0.51 - $1.17 $371,287 - $851,776	728,014 Added 88.9%	1,546,904 $913,000
Q1 2022 May 16, 2022	BUY	$0.65 - $1.18 $416,908 - $756,849	641,398 Added 361.37%	818,890 $876,000
Q4 2021 Feb 14, 2022	SELL	$0.86 - $1.7 $627,239 - $1.24 Million	-729,348 Reduced 80.43%	177,492 $195,000
Q3 2021 Nov 15, 2021	SELL	$1.27 - $8.17 $184,688 - $1.19 Million	-145,424 Reduced 13.82%	906,840 $1.2 Million
Q2 2021 Aug 16, 2021	BUY	$6.55 - $8.98 $2.27 Million - $3.11 Million	346,091 Added 49.01%	1,052,264 $7.98 Million
Q1 2021 May 17, 2021	BUY	$6.1 - $7.69 $452,113 - $569,959	74,117 Added 11.73%	706,173 $4.68 Million
Q4 2020 Feb 16, 2021	BUY	$5.05 - $7.1 $2 Million - $2.82 Million	396,508 Added 168.33%	632,056 $4.09 Million
Q3 2020 Nov 16, 2020	SELL	$5.25 - $7.08 $610,674 - $823,538	-116,319 Reduced 33.06%	235,548 $1.24 Million
Q2 2020 Aug 14, 2020	BUY	$5.37 - $8.11 $1.4 Million - $2.11 Million	260,320 Added 284.36%	351,867 $2.44 Million
Q1 2020 May 14, 2020	BUY	$4.35 - $8.79 $398,229 - $804,698	91,547 New	91,547 $520,000
Q4 2019 Feb 14, 2020	SELL	$4.23 - $8.29 $106,185 - $208,103	-25,103 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.15 - $6.28 $53,971 - $157,646	25,103 New	25,103 $117,000
Q1 2019 May 14, 2019	SELL	$1.88 - $3.35 $330,992 - $589,801	-176,060 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $238,625 - $598,000	-143,750 Reduced 44.95%	176,060 $315,000
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $2.86 Million - $3.55 Million	-763,389 Reduced 70.48%	319,810 $1.39 Million
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $2.44 Million - $3.82 Million	658,688 Added 155.16%	1,083,199 $4.01 Million
Q1 2018 May 15, 2018	BUY	$5.05 - $7.9 $835,052 - $1.31 Million	165,357 Added 63.81%	424,511 $2.14 Million
Q4 2017 Feb 14, 2018	BUY	$4.85 - $7.8 $606,953 - $976,131	125,145 Added 93.39%	259,154 $1.71 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $582,939 - $763,851	134,009	134,009 $750,000

Others Institutions Holding ARDX

# of Institutions

227

Shares Held

170M

Call Options Held

611K

Put Options Held

2.3M

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $866M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account